Aortic valve function post-replacement of severe aortic stenosis by transcatheter procedure versus surgery: a systematic review and metanalysis by Abi Khalil, Charbel et al.
1
Vol.:(0123456789)
Scientific Reports |        (2021) 11:11975  | https://doi.org/10.1038/s41598-021-91548-x
www.nature.com/scientificreports
Aortic valve function 
post‑replacement of severe 
aortic stenosis by transcatheter 
procedure versus surgery: 
a systematic review 
and metanalysis
Charbel Abi Khalil1,2,3*, Barbara Ignatiuk3,4,11, Guliz Erdem3,5,11, Hiam Chemaitelly1, 
Fabio Barilli6, Mohamed El‑Shazly1,7, Jassim Al Suwaidi1, Samar Aboulsoud8, Markus Kofler8, 
Lukas Stastny9, Hani Jneid10,11 & Nikolaos Bonaros3,9,11
Transcatheter aortic valve replacement (TAVR) has shown to reduce mortality compared to surgical 
aortic valve replacement (sAVR). However, it is unknown which procedure is associated with better 
post‑procedural valvular function. We conducted a meta‑analysis of randomized clinical trials that 
compared TAVR to sAVR for at least 2 years. The primary outcome was post‑procedural patient‑
prosthesis‑mismatch (PPM). Secondary outcomes were post‑procedural and 2‑year: effective orifice 
area (EOA), paravalvular gradient (PVG) and moderate/severe paravalvular leak (PVL). We identified 6 
trials with a total of 7022 participants with severe aortic stenosis. TAVR was associated with 37% (95% 
CI [0.51–0.78) mean RR reduction of post‑procedural PPM, a decrease that was not affected by the 
surgical risk at inclusion, neither by the transcatheter heart valve system. Postprocedural changes in 
gradient and EOA were also in favor of TAVR as there was a pooled mean difference decrease of 0.56 
(95% CI [0.73–0.38]) in gradient and an increase of 0.47 (95% CI [0.38–0.56]) in EOA. Additionally, self‑
expandable valves were associated with a higher decrease in gradient than balloon ones (beta = 0.38; 
95% CI [0.12–0.64]). However, TAVR was associated with a higher risk of moderate/severe PVL (pooled 
RR: 9.54, 95% CI [5.53–16.46]). All results were sustainable at 2 years.
Degenerative cardiovascular disease is becoming increasingly prevalent in industrialized countries, due essen-
tially to the aging of the  population1,2. Aortic stenosis (AS), the most common valvular heart disease in elderly, 
is associated with high morbidity and  mortality3. Surgical aortic valve replacement (sAVR) has been the gold-
standard method to repair severe AS for decades. However, transcatheter aortic valve replacement (TAVR) has 
emerged since 2002 as an alternative treatment that has the advantage of being minimally  invasive4, among 
several other technical  benefits5.
The clinical trial journey of TAVR started with the comparison to sAVR in high-risk surgery patients over a 
decade ago, included intermediate-risk ones some years ago, and ended with low-risk in 2019. All those trials have 
shown that TAVR is either non-inferior or even superior to sAVR in terms of mortality and other cardiovascular 
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 endpoints6–15. A first meta-analysis in 2016 regrouping high and intermediate risk patients confirmed those find-
ings and reported a significant 13% decrease in the relative risk of 2-year all-cause mortality in favor of  TAVR16. 
A recent update of this metanalysis that included new RCTs of low surgical-risk patients confirmed the benefit 
in favor of TAVR that was consistent in all surgical risk  groups17.
Both aortic valvular replacement techniques could be associated with post-operative functional complica-
tions. For instance, up to one third of patients experience high post-operative gradients due to a misbalance 
between the size of the aortic annulus and the orifice area required for an adequate blood  perfusion18. This 
condition known as patient-prosthesis mismatch (PPM) is related to diminished regression of the left ventricu-
lar mass, bioprosthetic valve dysfunction, symptoms recurrence and unfavorable clinical  outcome19. There is 
evidence of increased  mortality20 and early structural valve deterioration in patients with PPM after aortic valve 
 replacement21. Paravalvular regurgitation could also be encountered after valvular replacement. It is related to 
anatomical irregularities of the calcified tissue and leads to a functional leaking of the  valve22. Depending on its 
degree, this kind of regurgitation leads to a volume overload of the left ventricle which secondarily affects the 
pulmonary circulation and is associated with increased morbidity and mortality after the  procedure23.
Despite the safety, effectiveness and potential survival benefit of TAVR, there is a gap between the valve perfor-
mance assessment of this method and clinical outcomes. The aim of this systematic review and meta-analysis is to 
assess post-procedural echocardiographic parameters in patients with severe AS randomized to TAVR or sAVR.
Methods
Literature search. We performed a systematic literature search for randomized controlled trials (RCTs) 
using 3 databases: Medline, Embase and the Cochrane library, from the  1st of January 2002 till the 20th of 
December 2019 using specific search terms related to TAVR, sAVR and aortic stenosis/replacement (see supple-
mentary section). The systematic review was performed following the Preferred Reporting Items for Systematic 
Reviews and Meta-analyses (PRISMA)  guidelines24 and was registered with the International Prospective Regis-
ter of Systematic Reviews (PROSPERO identifier: CRD42018115963).
The search was done by 2 independent reviewers (BI, GE) without any language restriction. Any disagreement 
or inconsistency were resolved by a third reviewer (CAK). References of included trials were further screened 
for potential inclusion of eligible studies.
Eligibility criteria. We included RCTs that compared TAVR to sAVR in patients with severe AS, which had 
a follow-up duration of at least 2 years. Epidemiological data comparing TAVR to sAVR, trials that compared 
TAVR to any treatment other than sAVR or trials with a shorter follow-up duration were excluded.
Data extraction. Two independent reviewers extracted data (MK and LS) to a pre-specified data collection 
sheet. The following information were recorded: trial’s characteristics (name, registration number at clinicaltri-
als.gov, authors, year of publication) and design (methodology, number of randomized participants, outcome 
and follow-up duration), patients’ characteristics (age, gender, comorbidities, STS risk score), intervention 
(prosthesis type, access mode and balloon expansion). Finally, we collected outcome data related to echocar-
diographic parameters. Any disagreement or inconsistency on recorded data were resolved by another reviewer 
(NB). All data was extracted at 2 years in the “intention to treat” arms of the trials and was censored beyond that 
for trials with a longer follow-up period.
Quality assessment. We assessed the risk of bias in individual RCTs using the revised Cochrane risk of 
bias tool for randomized trials (RoB 2.0) that measures the risk of bias related to flaws in study design, rand-
omization process, conduct, outcome, analysis and reporting of the  data25. Overall bias was reported as low risk, 
some concerns and high-risk.
Outcomes of interest. The primary outcome was post-procedural patient-prosthesis-mismatch (PPM). 
PPM was graded according to the indexed effective orifice area (iEOA) after the procedure as follows: absence of 
PPM: iEOA > 0.85  cm2/m2 body surface area (BSA), moderate PPM: iEOA between 0.65 and 0.85  cm2/m2 BSA, 
severe PPM: iEOA < 0.65  cm2/m2 BSA. Secondary outcomes were post-procedural and 2-year: effective orifice 
area (EOA), paravalvular gradient (PVG) and moderate/severe paravalvular leak (PVL).
Statistical analysis. Forest plots were generated to visualize relative risks (RR) and standardized mean dif-
ference (SMD) estimates (for dichotomous and continuous outcomes, respectively) along with their associated 
95% CI, for each included RCT, post-procedure, and after 2 years.
Estimates for each outcome were then weighted using the inverse variance method, prior to being pooled 
using a DerSimonian-Laird random-effects  model26. This model assumes a normal distribution for true effect 
sizes (RR or SMD), therefore factoring in the heterogeneity across studies.
Subgroup meta-analyses stratified by patients’ surgical risk on inclusion (high, intermediate and low) or 
transcatheter heart valve system (balloon and self-expendable) were further performed.
Heterogeneity assessment was conducted by assessing Cochrane’s Q statistic and associated p-value to confirm 
existence of heterogeneity across studies, and  I2 to quantify the magnitude of between-study variation that is due 
to true differences in effect size rather than  chance27,28.
Univariable meta-regression analysis was also performed to examine and quantify the magnitude of the 
association between the risk of exposure to echocardiographic parameters post-procedure and at 2 years and 
patients’ surgical risk and transcatheter heart valve system. RR and β coefficients were calculated along with 
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their 95% CIs. Evidence for an association with risk of exposure to echocardiographic parameters was deemed 
“strong” at p value ≤ 0.05 and “good” at 0.05 < p value ≤ 0.1.
Analyses were performed using STATA/SE v15.1 (StataCorp. Stata Statistical Software: Release 15. College 
Station, TX: StataCorp LP; 2015).
Results
Our initial search identified 1729 studies from 3 different databases: Medline, Embase and Cochrane. After 
exclusion of duplicates, 912 studies were screened at the title/abstract level, of which only 18 were deemed to be 
eligible. Further screening at the full-text level identified 6 RCTs that were included in our meta-analysis (Fig. 1). 
 NOTION9, PARTNER  1A11, PARTNER  2A12,  SURTAVI13, EVOLUT Low  risk15 and US CoreValve high  risk29.
Baseline characteristics of the trials and patients are shown in Table 1. There was a total of 7020 participants, 
3511 randomized to TAVR and 3509 randomized to sAVR. Mean age of participants was 80 (3.5) years old, 
56.7% of participants were males, almost equally divided in both arms (TAVR arm: mean age is 80.2 (3.4) years 
old, 56.6% of males; sAVR arm: mean age is 80.4 (3.8) years old, 56.8% are males. All, but NOTION trial, were 
designed as non-superiority studies. Transfemoral was the most common access route, balloon expandable 
valves were used in 4 out of the 6 trials. 2 trials included high-risk patients: PARTNER  1A11 and US CoreValve 
Figure 1.  Risk of bias assessment. 
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high  risk29, 2 trials included intermediate-risk patients: PARTNER  2A12 and  SURTAVI13; and 2 included low-
risk patients:  NOTION9 and EVOLUT Low  risk15. All echocardiographic parameters were present except for 
post-procedural PPM for PARTNER 2A and SURTAVI trials. The risk of bias assessment was overall low (Sup-
plementary table 1).
Post‑procedural results. There was a 37% mean relative risk reduction (RR = 0.63, 95% CI [0.51–0.78]) in 
post-procedural PPM in favor of TAVR. This benefit was observed in high and low surgical risk groups (Fig. 2a), 
as well as in balloon and self-expendable valves (Fig. 2b) although at different magnitude.
The rest of echocardiographic measures were also in favor of TAVR, except for the PVL.
We observed a pooled mean decrease of 0.56 (95%CI [0.73–0.38]) in gradient. Sub-group analysis showed no 
difference in gradient between TAVR and sAVR across categories of surgical risk on inclusion (Fig. 3a) (p = 0.625). 
However, self-expendable valves were associated with a larger decrease in gradient than balloon ones (Fig. 3b) 
(β = − 0.38; 95% CI [− 0.64, − 0.12]). We also observed an overall increase of 0.47 (95% CI [0.38–0.56]) in EOA. 
However, the postoperative EOA did not differ between self-expandable and balloon expandable valves. The 
latter was consistent across subgroups (Fig. 4a,b). Finally, TAVR was associated with an almost tenfold increase 
in the risk of moderate/severe PVL (pooled RR: 9.54, 95% CI [5.53–16.46]), that was noticed in both subgroups 
(Fig. 5a,b).
2‑year outcome. A similar trend was observed at 2 years. We noted a pooled mean decrease of 0.59 (95%CI 
[0.29–0.89]) in gradient that was independent of the patient’s surgical risk at inclusion (Supplementary Fig. 1a). 
However, self-expandable valves were associated with a larger gradient decrease as compared to balloon-
expandable ones (β = − 0.62; 95%CI [− 0.85, − 0.40]) (Supplementary Fig. 11). Additionally, there was a pooled 
mean increase of 0.46 (95% CI [0.25–0.67]) in EOA that was significant in all surgical risk categories (Supple-
Table 1.  Trials and participants characteristics.
PARTNER 1A US CoreValve high risk NOTION PARTNER 2A SURTAVI Evolut Low risk





NCT00530894 NCT01240902 NCT01057173 NCT01314313 NCT01586910 NCT02701283
Number of 
centers 25 45 3 57 87 86
Design Non-inferiority Non-inferiority Non-inferiority Non-inferiority Non-inferiority Non-inferiority
Sample size 348 351 394 401 145 135 1011 1021 879 867 734 734
Recruitment 
period 2007–2009 2011–2012 2009–2013 2011–2013 2012–2016 2016–2018
Publication 
source/year Kodali et al.
11 Reardon et al.29 Sondergaad et al.9 Leon et al.12 Reardon et al.13 Popma et al.15
Patient’s risk High High Low Intermediate Intermediate Low
Participants characteristics
Age 
(years) ± SD 83.6 ± 6.8 84.5 ± 6.4 83.2 ± 7.1 83.5 ± 6.3 79.2 ± 4.9 79.0 ± 4.7 81.5 ± 6.7 81.7 ± 6.7 79.9 ± 6.2 79.8 ± 6.0 74.0 ± 5.9 73.8 ± 6.0
Males (%) 57.8 56.7 53.6 52.9 53.8 52.6 54.2 54.8 57.8 55.8 63.8 66.5





– – 51 (12.9%) 53 (13.2%) 24 (16.6%) 22 (16.3%) – – 59 (6.7%) 65 (7.5%) – –
LVEF, mean 




11.8 ± 3.3 11.7 ± 3.5 7.3 ± 3.0 7.5 ± 3.2 2.9 ± 1.6 3.1 ± 1.7 5.8 ± 2.1 5.8 ± 1.9 4.4 ± 1.5 4.5 ± 1.6 1.9 ± 0.7 1.9 ± 0.7
Intervention characteristics











ral 244 (70) 294 (100) 145 (100) 775 (77) 503 (100) 731 (99.6)
Transtho-
racic 140 (30) 0 (0) 0 236 (23) 0 (0) 3 (0.4)
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Figure 2.  Pooled mean difference of post-procedural patient-prosthesis-mismatch, according to (a) surgical 
risk on inclusion and (b) transcatheter heart valve system.
Figure 3.  Pooled mean difference of post-procedural gradient at 2 years, according to (a) surgical risk on 
inclusion and (b) transcatheter heart valve system. 
Figure 4.  Pooled mean difference of post-procedural effective orifice area at 2 years, according to (a) surgical 
risk on inclusion and (b) transcatheter heart valve system.
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mentary Fig. 2a). However, self-expendable-valves were associated with a larger increase in EOA compared to 
balloon ones (β = 0.35; 95% CI [0.01–0.70]) (Supplementary Fig. 2b). Finally, the risk of moderate/severe PVL 
was almost tenfold higher in patients who had a valvular replacement with TAVR two years earlier (pooled RR: 
10.20, 95%CI [4.84–21.49]). Those findings were consistent in both-groups (Supplementary Figs. 3a and 3b and 
4b).
Discussion
This meta-analysis focused on quantitative and qualitative echocardiographic outcomes reviewing RCTs that 
comparing TAVR and sAVR for the treatment of severe AS. The higher effective orifice areas of the aortic pros-
thesis and the lower residual gradients after TAVR speak for a more effective treatment of the disease by TAVR 
as compared to sAVR. The lower rates of PPM after TAVR also support the higher effectiveness of treatment by 
TAVR. These findings are certainly counterbalanced by the significantly lower rates of paravalvular regurgita-
tion in sAVR patients.
The major strength of the study is the acquisition of echocardiographic parameters with other hard clinical 
endpoints such as all-cause mortality. Studying echocardiographic parameters closes the gap of shortness of 
follow-up of several aortic stenosis RCTs. Those parameters are supposed to be the best predictors of mortality 
and morbidity after the treatment of AS. The echocardiographic results obtained by the meta-analysis may explain 
some of the differences between the two treatment arms in terms of mortality: TAVR has the advantage of low 
residual gradients (and lower rates of PPM) but the disadvantage of higher rates of paravalvular regurgitation. 
As both conditions can be associated with increased mortality, any improvement on the incidence of PVL in 
TAVR valve or PPM in surgical valve may let the cards be reshuffled again.
The studies included in the analysis refer to the use of SAPIEN and SAPIEN XT (represent the balloon 
expandable valves family) and Corevalve and Evolute R (self-expandable valves). A head-to-head comparison of 
the PARTNER 1, 2 and 3 trials demonstrate a gradual reduction of the rates of relevant paravalvular regurgitation 
(greater than or equal to moderate) from 12.2, to 3.4%, to 0.8%, respectively. Mild paravalvular regurgitation 
was detected in 65.2%, to 20.4%, to 28.7% respectively. The impact of paravalvular regurgitation on mortality 
was significant in patients with PVL greater than or equal to mild in the PARTNER I trial and PVL greater than 
moderate in PARTNER 2. This discrepancy is most probably related to the fact that the numbers of patients with 
paravalvular regurgitation dropped overtime and the PARTNER 2 trial was underpowered to address the effect 
of mild PV-leak in those patients. As demonstrated by the results, the numbers of PV leaks greater than trace 
significantly change between the SAPIEN and SAPIEN XT prosthesis, but not between SAPIEN XT and SAPIEN 
3 in those randomized studies. The same trend is observed for self-expandable valves too. Taken together, the 
results indicate a trend for decreased paravalvular regurgitation greater than or equal to moderate, but the overall 
occurrence of the finding remained unchanged. There are some observational studies demonstrating improved 
results in the newest generation of transcatheter valves, however their real impact on hard clinical outcomes is 
still  unknown30.
Interestingly we demonstrated that there are differences in EOA, transvalvular gradients and PPM not only 
between the two treatment arms but also within the TAVR valves. Self-expandable valves have been found to be 
more advantageous than balloon-expandable valves. This is also supported by registry data in the  literature31. 
However, literature data demonstrate a higher incidence of PVL in self-expandable valves, though this has not 
been investigated in our  analysis32. From this point of view, our meta-analysis provides first evidence that patients 
at risk for PPM may benefit from transcatheter treatment especially by using a self-expandable valve. On the 
other hand, patients at risk for PVL should be rather treated by conventional surgery. From a different angle, 
our results are completely aligned with a recent meta-analysis that compared only PPM in both procedures 
and reported a benefit towards TAVR irrespective of the study design, severity of the disease and follow-up 
 period33. All randomized trials included into the meta-analysis were related to the surgical risk assessed by 
Figure 5.  Pooled relative risk of post-procedural moderate/severe paravalvular leak, according to (a) 
transcatheter heart valve system and (b) surgical risk on inclusion.
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common surgical risk scores. The most important lesson from those trials is that the surgical risk may affect 
the perioperative and mid-term survival of sAVR as well as the mid-term survival of TAVR patients but not the 
perioperative survival of the latter. The anatomical risk on the degree and distribution of calcification as well as 
the presence of a bicuspid valve or left ventricular outflow tract (LVOT) calcifications has been associated with 
inferior results in  TAVR34–36. This knowledge became more evident during the evolution of TAVR and patients 
with high anatomical risk conditions have been excluded from randomization. Still the surgical risk is very well 
depicted in patients’ selection of the different trials and has been separately analyzed in Figs. 2, 3, 4 and 5. As 
expected, the surgical risk did not affect residual gradients, the effective orifice area after treatment, nor the rates 
of paravalvular regurgitation.
Our results at 2 years confirmed the immediate postoperative results and indicate that the margin of changes 
both in terms of EOA and residual gradients, as well as PVL is very small at mid-term. Whether those differences 
reflect the long-term echo findings and affect valve function in the long run is still unknown. The presence of the 
calcified aortic valve tissue near the bioprosthetic valve, the crimping manipulation and the non-circular expan-
sion of the transcatheter valve prosthesis may turn the scales towards conventional surgical  prostheses37. Up to 
now, the effect of crimping on the pericardial tissue was not associated with any clinical disadvantage. However, 
there are laboratory trials demonstrating irreversible tissue damage on pericardial leaflets especially in aggres-
sive crimping manoeuvres (< 16 French)38,39. On the other hand, the presence of a surgical sutures and Teflon 
 pledges40 in the left ventricular outflow tract and the crown-shaped design of a common surgical bioprosthesis 
may increase turbulences within the heart cycle and promote  thrombogenicity41. The latter is a known factor of 
early valve dysfunction and degeneration.
We acknowledge the presence of some limitations in our study. Although the overall risk of bias was low, 
there are still some possibilities of outcome measurement bias in the studies, especially for the measurement of 
echocardiographic parameters that are operator- and technique- dependent. As pointed out by the subgroup 
analysis, the type of prosthesis may also play a role at the high degree of heterogeneity of the echocardiography 
results. The use of different types of prosthesis was only investigated within the TAVR arm, due to the lack of 
data at the surgical arm. Although surgical prostheses do not variate a lot, some degree of heterogeneity on the 
grounds of prostheses differences cannot be excluded. All studies included different models of the same prosthesis 
including also early generation devices. Newer TAVR prostheses are associated with lower rates of paravalvular 
leak, whereas newer surgical prostheses are related to improved EOA and residual gradients. To which extent this 
variability in both treatment arms has influenced all types of outcomes presented in the meta-analysis remains 
unknown. The eligibility criteria for recruitment in the studies included were based on risk stratification. The 
latter was performed by using scores which were basically developed for surgical patients. The use of the STS 
PROM score is widely accepted -mainly due to the lack of alternatives-, however this score may not accurately 
reflect the perioperative risk after TAVR. The inclusion criteria for eligible participants in prospective randomized 
trials are carefully selected and may not always reflect daily  practice42. However, the majority of data from audited 
national and multicenter registries mostly confirm the presented results. Finally, with only 6 trials included in 
our meta-analysis, it was not possible to perform a meta-regression that takes into account confounding factors 
like age, gender and cardiovascular risk factors.
Conclusion
The effective orifice area, the transvalvular gradients and the patient-prosthesis mismatch favor transcatheter 
aortic valve replacement over surgery for the treatment of severe aortic stenosis in our metanalysis. This benefit 
is counterbalanced by higher rates of paravalvular regurgitation. Nevertheless, the effect of newer generation 
prostheses both in transcatheter and in surgical aortic valve replacement still needs to be determined. Future 
research should focus on the effect of these echocardiographic differences on clinical outcomes.
Data availability
The data that support the findings of this study are available from the authors upon reasonable request from the 
corresponding author.
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